![]() ![]() ![]() The linker that connects payload and antibody is then cleaved, and the payload released into the cytoplasm, where it finally induces cell apoptosis via its cytotoxic pathway. Upon binding with the cell surface antigen targeted by the specific antibody, the ADC is internalized by the tumor cell and processed by the endo-lysosomal system. This review aims at providing a summary of the technology behind these compounds and at presenting the latest ADCs approved in solid tumors, as well as at describing novel targets for ADCs under investigation and new strategies to optimize their efficacy in solid tumors.Īntibody–drug conjugates (ADCs) are complex targeted agents composed by a cytotoxic drug hanging on an antibody scaffold. Several novel ADCs are under evaluation, exploring new potential targets along with innovative payloads. Thanks to progressive advances in engineering technologies these drugs rely on, the spectrum of diseases sensitive to these drugs as well as their indications are in continuous expansion. Three novel ADCs have been recently approved, i.e., trastuzumab deruxtecan, sacituzumab govitecan and enfortumab vedotin, respectively, targeting HER2, Trop2 and Nectin4. They are commonly described as the “Trojan Horses” of therapeutic armamentarium, because of their capability of directly conveying cytotoxic drug (payloads) into the tumor space, thus transforming chemotherapy into a targeted agent. Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to merge the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. ![]()
0 Comments
Leave a Reply. |